SCHEMBL263430

SCHEMBL263430

COc1cc(Cl)cc(-c2ccc(N)nc2N)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.43
HSP90AB1 P08238 2/20 0.43
SCN10A Q9Y5Y9 3/20 0.42
SCN2A Q99250 3/20 0.42
SCN9A Q15858 2/20 0.42
SCN3A Q9NY46 2/20 0.42
SCN1A P35498 1/20 0.42
KCNH2 Q12809 1/20 0.42
SCN5A Q14524 1/20 0.42
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
AGPAT2 O15120 9/20 0.39
RECQL P46063 1/20 0.38
MCHR1 Q99705 1/20 0.37
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27776400 0.84 HSP90AA1 (0.55) HSP90AA1HSP90AB1SCN10AALDH1A1KDM4E
SCHEMBL262436 0.79 SCN10A (0.57) HSP90AA1HSP90AB1SCN10ASCN2ASCN9A
SCHEMBL2416618 0.77 SCN2A (0.67) HSP90AA1HSP90AB1SCN10ASCN2AALDH1A1
SCHEMBL14237425 0.76 PTPN11 (0.48) HSP90AA1HSP90AB1SCN10ASCN2ASCN9A
SCHEMBL21223692 0.73 ALDH1A1 (0.55) ALDH1A1KDM4E
SCHEMBL21223648 0.72 APP (0.52) HSP90AA1HSP90AB1ALDH1A1KDM4EMCHR1
SCHEMBL21223549 0.72 MCHR1 (0.42) KCNH2MCHR1GSK3B
SCHEMBL21223583 0.71 AGPAT2 (0.46) HSP90AA1HSP90AB1SCN10AAGPAT2
SCHEMBL263442 0.71 SCN10A (0.58) HSP90AA1HSP90AB1SCN10ASCN9ASCN1A
SCHEMBL263262 0.70 SCN10A (0.56) HSP90AA1HSP90AB1SCN10ASCN2ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 HSP90AA1 3017/4885HSP90AB1 2707/4885SCN10A 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.